Page last updated: 2024-12-06

n-ethyl-3-piperidyl benzilate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-ethyl-3-piperidyl benzilate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62504
CHEMBL ID342669
SCHEMBL ID1742170
MeSH IDM0064300

Synonyms (33)

Synonym
epb (van)
benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 1-ethyl-3-piperidinyl ester
nsc 524174
brn 0309916
3-piperidinol, 1-ethyl-, benzilate (ester)
dea no. 7482
ditran jb 318
3-piperidinol, benzilate (ester)
n-ethyl-3-piperidyl benzilate
nsc-524174
benzilic acid, 1-ethyl-3-piperidyl ester
nsc524174
1-ethyl-3-piperidyl benzilate
benzeneacetic acid, 1-ethyl-3-piperidinyl ester
wln: t6mtj covxqr&r& c2
3567-12-2
epb ,
jb 318
CHEMBL342669 ,
(1-ethylpiperidin-3-yl) 2-hydroxy-2,2-diphenylacetate
02j52696mz ,
4-21-00-00029 (beilstein handbook reference)
unii-02j52696mz
SCHEMBL1742170
benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl-, 1-ethyl-3-piperidinyl ester
OJYOTLHNSMYONM-UHFFFAOYSA-N
n-ethyl-3-piperidylbenzilate
bdbm50473046
(1-ethyl-3-piperidyl) 2-hydroxy-2,2-diphenyl-acetate
benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 1-ethyl-3-piperidinyl ester (9ci)
Q6951360
DTXSID20863199
1-ethyl-3-piperidinyl alpha-hydroxy-alpha-phenylbenzeneacetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.00150.00010.579710.0000AID142341
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.00150.00011.48339.1400AID142341
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.00150.00010.68688.2600AID142341
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.00150.00010.66618.2600AID142341
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.00150.00010.58908.2600AID142341
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID24405Partition coefficient (logP)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Synthesis, (18)F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors.
AID142341Tested in vitro for binding affinity against Muscarinic acetylcholine receptor from rat brain using [3H]- Scopolamine as radioligand2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Synthesis, (18)F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]